Journal of Drug TargetingPub Date : 2026-12-01Epub Date: 2026-06-02DOI: 10.1080/1061186X.2026.2680982
Adil Sher, Ahmad Sohail, Adnan Gul, Ali Shan, Khair Zman, Abid Ali, Gauhar Rehman
{"title":"Green synthesis and characterization of silver nanoparticles using <i>Asparagus officinalis</i> and their anti-inflammatory and antioxidant activities: <i>in silico</i>, <i>in vitro</i>, and <i>in vivo</i> studies.","authors":"Adil Sher, Ahmad Sohail, Adnan Gul, Ali Shan, Khair Zman, Abid Ali, Gauhar Rehman","doi":"10.1080/1061186X.2026.2680982","DOIUrl":"10.1080/1061186X.2026.2680982","url":null,"abstract":"<p><p>Herbal medicines for managing prevalent health conditions, inflammatory disorders, and oxidative stress have attracted growing scientific attention. This study reports the green synthesis of silver nanoparticles (AgNPs) using <i>Asparagus officinalis</i> root extract, which served as both a reducing and stabilising agent, and evaluates their antioxidant and anti-inflammatory potential. The biosynthesized AO-Ag-NPs were characterised by UV-Visible (UV-Vis) spectroscopy, Fourier-transform infra-red (FTIR) spectroscopy, X-ray diffraction (XRD), and scanning electron microscopy (SEM). <i>In vitro</i> anti-inflammatory activity was assessed using HRBC membrane stabilisation, heat-induced haemolysis, and protein denaturation assays, while antioxidant potential was assessed with the DPPH free radical-scavenging assay. AO-Ag-NPs exhibited superior antioxidant activity (79.66 ± 1.11%) compared to the ethanolic root extract (64.76 ± 2.61%) at 30 µg/mL. In anti-inflammatory assays, AO-Ag-NPs inhibited HRBC membrane stabilisation by 81.56 ± 1.08%, heat-induced haemolysis by 83.57 ± 1.07%, and protein denaturation by 88.31 ± 0.94%, outperforming the root extract and approaching the standard drug. <i>In vivo</i> evaluation using a xylene-induced ear edoema mouse model confirmed the significant anti-inflammatory effects of AO-Ag-NPs. Molecular docking studies further supported these results, showing Kaempferol interacting with NF-κB at -6.50 kcal/mol, forming hydrogen bonds and Pi-H interactions, while ferulic acid and hexamethylcyclotrisiloxane exhibited favourable binding with Keap1 (-5.79 and -4.26 kcal/mol, respectively), involving key amino acid residues. These findings indicate that both <i>A. officinalis</i> ethanolic root extract and its green-synthesised AgNPs possess potent antioxidant and anti-inflammatory activities. The study highlights the potential of AO-Ag-NPs as natural therapeutic agents and provides a foundation for developing herbal-based nanomedicine for managing oxidative stress and inflammation-related disorders.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"2055-2066"},"PeriodicalIF":4.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148031366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of Drug TargetingPub Date : 2026-12-01Epub Date: 2026-06-19DOI: 10.1080/1061186X.2026.2689072
Reza Zolfaghari Emameh
{"title":"Carbonic anhydrase modulation in the tumour microenvironment: synergistic pathways with oncolytic viruses in gastrointestinal malignancies.","authors":"Reza Zolfaghari Emameh","doi":"10.1080/1061186X.2026.2689072","DOIUrl":"10.1080/1061186X.2026.2689072","url":null,"abstract":"<p><p>Gastrointestinal (GI) malignancies are leading causes of global cancer mortality, with advanced stages showing pronounced therapeutic resistance. A key driver of this aggression is the immunosuppressive and acidic tumour microenvironment (TME). This niche is critically regulated by hypoxia-inducible carbonic anhydrase (CA) isoforms IX and XII. These enzymes catalyse extracellular carbon dioxide hydration, acidifying the milieu to promote invasion, metastasis and immune evasion. Pharmacological CA IX/XII inhibition counteracts this by normalising pH, reducing invasiveness and reinvigorating anti-tumour immunity. Oncolytic viruses (OVs) represent a complementary immunotherapeutic modality. Engineered to selectively replicate in tumour cells, OVs induce direct cytolysis and immunogenic cell death, thereby stimulating systemic immunity. However, their efficacy is hindered by the very acidosis sustained by CA activity. This establishes a compelling synergy: CA inhibition alleviates the acidic barrier to enhance OV spread and potency. Conversely, OV-mediated lysis disrupts hypoxic tumour regions, subsequently downregulating CA IX/XII expression and mitigating acidification. This bidirectional, self-reinforcing cycle positions their combination as a rational strategy to dismantle the TME's metabolic and immunological defences. Preclinical evidence supports that this multimodal approach enhances tumour regression, suppresses metastasis and prolongs survival, offering a promising translational paradigm for GI cancers.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1993-2010"},"PeriodicalIF":4.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148251958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of Drug TargetingPub Date : 2026-12-01Epub Date: 2026-07-07DOI: 10.1080/1061186X.2026.2697913
Regan Charles R, Subhasis Sarangi, Aranganathan V
{"title":"Dual-responsive hydrogel-coated nanoclusters for combined magnetic hyperthermia and drug delivery: a comprehensive <i>in vitro</i> and <i>in vivo</i> toxicity profiling.","authors":"Regan Charles R, Subhasis Sarangi, Aranganathan V","doi":"10.1080/1061186X.2026.2697913","DOIUrl":"10.1080/1061186X.2026.2697913","url":null,"abstract":"<p><p>Cancer therapy demands smarter, more targeted strategies that minimise healthy tissue damage while maximising therapeutic efficacy. This study introduces Hy-Si-IONC, a dual heat- and pH-responsive hydrogel-coated magnetic nanocluster, engineered to deliver chemotherapeutic drug within the tumour microenvironment. When combined with magnetic hyperthermia, it offers targeted, localised drug release, outperforming conventional single-stimulus carriers. The encapsulation efficiency and drug loading capacity of the Hy-Si-IONC were 47.3% and 4.6%, respectively. Hy-Si-IONC exhibited a lower critical solution temperature (LCST) of 43 °C with drug-release potential of 41.89% under tumour-mimicking conditions. A combinational therapy of doxorubicin-loaded Hy-Si-IONC and magnetic hyperthermia reduced the cell viability to 18% in MDA-MB-231 cells, confirming a strong therapeutic effect between thermal and chemotherapy. The nanosystem displayed good compatibility with human lymphocytes, MCF-7 and MDA-MB-231 cell lines. Haemolysis remained below 1%, and no genotoxicity was detected. Long-term <i>in vivo</i> safety was confirmed in a 25-week mice study; the nanoclusters predominantly accumulated in the liver and spleen. Transient changes in antioxidant markers - superoxide dismutase (SOD), catalase, glutathione S-transferase (GST), and glutathione (GSH) normalised by the end of the study. No major histopathological abnormalities were observed in vital organs. Collectively, Hy-Si-IONC presents a biocompatible and potential dual-modal cancer therapy.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"2158-2178"},"PeriodicalIF":4.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of Drug TargetingPub Date : 2026-12-01Epub Date: 2026-09-20DOI: 10.1080/1061186X.2026.2735536
{"title":"Statement of Retraction.","authors":"","doi":"10.1080/1061186X.2026.2735536","DOIUrl":"10.1080/1061186X.2026.2735536","url":null,"abstract":"","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"2179"},"PeriodicalIF":4.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Integrating antibody-drug conjugates, multispecific antibodies, targeted protein degradation and nanomedicine in precision oncology.","authors":"Imran Ali, Mir Faiza, Arshad Mehmood, Zhiping Wang, Zhang Fang, Xinyu Zhang","doi":"10.1080/1061186X.2026.2687011","DOIUrl":"10.1080/1061186X.2026.2687011","url":null,"abstract":"<p><p>Molecular engineering, chemical biology and translational oncology have transformed the landscape of targeted cancer therapies. Antibody-drug conjugates (ADCs) have advanced into clinically validated platforms that combine antigen-specific recognition with potent cytotoxic payloads, supported by innovations in linker chemistry, drug-to-antibody ratio (DAR) optimisation, and bispecific or multispecific antigen targeting. Parallel to ADC development, targeted protein degradation (TPD) technologies - proteolysis-targeting chimaeras (PROTACs), molecular glues, and emerging lysosomal and autophagy-based degraders enable the catalytic elimination of oncogenic drivers that were previously considered undruggable. Nanomedicine-based delivery enhances therapeutic selectivity, improves pharmacokinetics and overcomes barriers to intracellular drug transport. Rational combination therapies that integrate these platforms with immune checkpoint inhibitors, kinase inhibitors and tumour microenvironment (TME)-modulating agents address tumour heterogeneity and adaptive resistance more effectively than monotherapies. This review synthesises the foundations of ADCs, multispecific antibodies, protein degraders, nanomedicine platforms, targeted small-molecule inhibitors and their combination strategies. Clinically, the convergence of these modalities promises to extend durable responses to patient populations with refractory, molecularly complex malignancies by enabling individualised, mechanism-driven therapeutic selection.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1976-1992"},"PeriodicalIF":4.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148271695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of Drug TargetingPub Date : 2026-12-01Epub Date: 2026-06-28DOI: 10.1080/1061186X.2026.2694521
Zhenhua Guan, Yi Xu, Xuyang Liang, Jing Chen, Mengjie Li, Xueliang Li
{"title":"Physcion-loaded, folic acid-conjugated DSPE-PEG liposomes for targeted therapy of ulcerative colitis.","authors":"Zhenhua Guan, Yi Xu, Xuyang Liang, Jing Chen, Mengjie Li, Xueliang Li","doi":"10.1080/1061186X.2026.2694521","DOIUrl":"10.1080/1061186X.2026.2694521","url":null,"abstract":"<p><p>Conventional ulcerative colitis (UC) therapies suffer from limited efficacy and toxicity. Although physcion (PHY) has multi-target anti-inflammatory activity, its poor solubility and lack of targeting restrict clinical use. To overcome these issues, we developed folate receptor (FR)-targeted DSPE-PEG liposomes encapsulating PHY using thin-film hydration and central composite design optimization. The resulting liposomes showed uniform size (approximately 160 nm, PDI < 0.18), high entrapment efficiency (>92%), and good stability. In vitro release was significantly improved, and cellular uptake was enhanced in inflammatory EC cells via FR-mediated endocytosis. Pharmacokinetic studies revealed prolonged half-life and increased bioavailability, while tissue distribution confirmed colon-specific enrichment. In DSS-induced UC mice, targeted liposomes repaired colonic mucosa, reduced fibrosis, suppressed pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), and alleviated oxidative stress through coordinated NF-κB/Nrf2 regulation, with efficacy superior to conventional liposomes and positive controls. Safety assessments showed no notable cytotoxicity to normal cells. This work offers a promising FR-targeted nanocarrier to overcome PHY's clinical limitations and provides a foundation for targeted UC therapy.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"2136-2157"},"PeriodicalIF":4.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148308236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dendrimer-mediated therapy and recovery for stroke: a comprehensive review.","authors":"Zainab Lafi, Sherine Asha, Rotana Walid Abu-Obaida","doi":"10.1080/1061186X.2026.2683980","DOIUrl":"10.1080/1061186X.2026.2683980","url":null,"abstract":"<p><p>Stroke is a leading cause of mortality and long-term disability worldwide, with ischaemic stroke accounting for the majority of cases. Current therapies, including thrombolysis and supportive care, are limited by narrow therapeutic windows, eligibility restrictions, and the brain's limited regenerative capacity, leaving many patients with persistent neurological deficits. Nanotechnology has emerged as a promising strategy to overcome these limitations, offering targeted delivery of therapeutic agents across the blood-brain barrier and modulation of key pathological processes such as oxidative stress and neuroinflammation. Among various nanocarriers, dendrimers, highly branched, nanosized polymers with internal cavities, have demonstrated potential for targeted drug delivery and enhanced neuroprotection in experimental stroke models. This review summarises the design features, therapeutic applications, and current challenges of dendrimer-based nanocarriers, demonstrating their potential to improve stroke therapy and recovery.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1926-1943"},"PeriodicalIF":4.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Design of a novel nano-lipoidal gel system for topical delivery of hydroxychloroquine in rheumatoid arthritis.","authors":"Ankit Raj, Pradip Nirbhavane, Ashish Dilip Sutar, Rahul Shukla, Atin Kalra, Satish Sardana","doi":"10.1080/1061186X.2026.2683971","DOIUrl":"10.1080/1061186X.2026.2683971","url":null,"abstract":"<p><p>Hydroxychloroquine (HCQ) is widely used in management of rheumatoid arthritis. However, its moderate bioavailability and serious systemic adverse effects limit its therapeutic utility for long term administration. A potential way to overcome these limitations is to develop topical dosage form of the drug, based on nanocarriers for better drug permeation. The nanoformulation was developed using biocompatible lipids and optimized using Box-Behnken experimental design. The optimized nanoformulation had a mean particle size of 110 nm, a polydispersity index of 0.11 and an entrapment efficiency of 84%. The formulation was further incorporated into a Carbopol 934 gel and evaluated for <i>in vitro</i>, <i>ex vivo</i>, and <i>in vivo</i> behaviour as well as therapeutic efficacy. Compared to the conventional gel, the nanogel formulation exhibited higher and sustained release of HCQ over a 24-hour period (67% vs 50%), penetrated the skin more readily (66%), and deposited more amount of drug in the deeper layers of skin. The formulation demonstrated significant anti-inflammatory activity, as measured by 76% inhibition of protein denaturation; <i>in vivo</i> efficacy (24% inhibition of paw edema) and good physicochemical for 6 months. Thus, HCQ nanogel formulation represents a promising transdermal drug delivery system for the better management of rheumatoid arthritis.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"2081-2097"},"PeriodicalIF":4.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of Drug TargetingPub Date : 2026-12-01Epub Date: 2026-06-16DOI: 10.1080/1061186X.2026.2686235
Sweetmama Pradhan, Dinesh Kumar Sharma
{"title":"Emerging trends of nanotechnology-based drug delivery for wound healing.","authors":"Sweetmama Pradhan, Dinesh Kumar Sharma","doi":"10.1080/1061186X.2026.2686235","DOIUrl":"10.1080/1061186X.2026.2686235","url":null,"abstract":"<p><p>Wound healing is a complex, dynamic and multistep biological process involving haemostasis, inflammation, proliferation and remodelling, which can be severely compromised in chronic, infected, or non-healing wounds. Conventional wound care strategies often suffer from limitations such as poor drug stability, inadequate tissue penetration, frequent dressing changes and a lack of spatiotemporal control over therapeutic release. In recent years, nanotechnology-based drug delivery systems have emerged as promising platforms to overcome these challenges by enabling targeted, controlled and multifunctional therapeutic interventions. This comprehensive review highlights emerging trends in nanotechnology-driven approaches for wound healing, with a focus on their design and therapeutic potential across different stages of wound repair. The review systematically discusses major nanotechnological platforms, including electrospun nanofibers, advanced hydrogel systems, nanocomposites, polymeric micelles and a wide range of inorganic nanoparticles such as silver, gold, copper, silica and titanium dioxide nanoparticles. Additionally, advanced materials such as graphene and scaffold-based systems, including scaffold-integrated nanoparticles and hydrogel-based scaffolds, are critically examined for their roles in promoting angiogenesis, antimicrobial activity, cell migration and tissue regeneration. Ultimately, this review provides valuable insights into future perspectives and research directions, highlighting the need for multifunctional nanoplatforms to advance next-generation wound healing therapies.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1963-1975"},"PeriodicalIF":4.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148199144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of Drug TargetingPub Date : 2026-12-01Epub Date: 2026-06-16DOI: 10.1080/1061186X.2026.2687007
Jaghatha Therassama, Justus Oliver Jaslin Edward, Somasundaram Arumugam, Pavazhaviji Pazhani, Jose Prakash Dharmian
{"title":"Intranasal dalfampridine-loaded mucoadhesive polymeric nanoparticles for brain targeting: formulation and therapeutic evaluation in a cuprizone-induced demyelination model.","authors":"Jaghatha Therassama, Justus Oliver Jaslin Edward, Somasundaram Arumugam, Pavazhaviji Pazhani, Jose Prakash Dharmian","doi":"10.1080/1061186X.2026.2687007","DOIUrl":"10.1080/1061186X.2026.2687007","url":null,"abstract":"<p><p>The present study aimed to develop and comprehensively evaluate dalfampridine-loaded chitosan nanoparticles (DLM-CSNPs) for enhanced intranasal brain delivery in a cuprizone-induced demyelination model of multiple sclerosis (MS). The optimised nanoparticles were found to have a particle size of 166.5 nm with PDI 0.24, a positive surface charge (Zeta Potential +24.97 mV), and high entrapment efficiency (82%). <i>Ex Vivo</i> Permeation studies demonstrated that the permeation rate of the drug from DLM-CSNPs (902.26 µg/cm<sup>2</sup>) was significantly higher compared to the drug solution (609.96 µg/cm<sup>2</sup>). Sub-acute toxicity studies indicated the lack of significant systemic, hepatic, and renal toxicity of the compound after 28 days of repeated intranasal administration, even at a dose of 4 mg/kg. Pharmacokinetic studies indicated the better targeting of the brain by the intranasal route, where the brain Cmax was two-fold higher, brain AUC 0-12 was significantly higher, brain Tmax was significantly lower, and the brain/plasma ratios were significantly higher compared to the oral route. When compared to the traditional oral route of administration, the intranasal DLM-CSNPs treatment has demonstrated improved delivery of the formulation to the central nervous system, functional recovery, decreased neuroinflammation, and neuroprotective effects, suggesting the therapeutic potential of the DLM-CSNPs formulation for the management of multiple sclerosis.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"2098-2121"},"PeriodicalIF":4.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148217370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}